NO20052462L - Kombinasjonsterapi under anvendelse av 1-aminosykloheksanderivater og acetyl-cholinesteraseinhibitorer - Google Patents

Kombinasjonsterapi under anvendelse av 1-aminosykloheksanderivater og acetyl-cholinesteraseinhibitorer

Info

Publication number: NO20052462L
Authority: NO; Norway
Prior art keywords: combination therapy; acetylcholinesterase inhibitors; cyclohexane derivatives; amino cyclohexane; amino
Prior art date: 2002-10-24

Application number

NO20052462A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052462D0 (no

Inventor

Hans-Joerg Moebius

Original Assignee

Merz Pharma Gmbh & Co Kgaa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-24

Filing date

2005-05-23

Publication date

2005-07-20

2005-05-23 Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa

2005-05-23 Publication of NO20052462D0 publication Critical patent/NO20052462D0/no

2005-07-20 Publication of NO20052462L publication Critical patent/NO20052462L/no

Links

239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
238000002648 combination therapy Methods 0.000 title abstract 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 title abstract 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
229960003530 donepezil Drugs 0.000 abstract 1
239000000890 drug combination Substances 0.000 abstract 1
229960003980 galantamine Drugs 0.000 abstract 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
229960004640 memantine Drugs 0.000 abstract 1
OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 abstract 1
229950004543 neramexane Drugs 0.000 abstract 1
229960004136 rivastigmine Drugs 0.000 abstract 1
229960001685 tacrine Drugs 0.000 abstract 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20052462A 2002-10-24 2005-05-23 Kombinasjonsterapi under anvendelse av 1-aminosykloheksanderivater og acetyl-cholinesteraseinhibitorer NO20052462L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42091802P	2002-10-24	2002-10-24
PCT/GB2003/004549 WO2004037234A2 (en)	2002-10-24	2003-10-23	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

Publications (2)

Publication Number	Publication Date
NO20052462D0 NO20052462D0 (no)	2005-05-23
NO20052462L true NO20052462L (no)	2005-07-20

Family

ID=32176649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052462A NO20052462L (no)	2002-10-24	2005-05-23	Kombinasjonsterapi under anvendelse av 1-aminosykloheksanderivater og acetyl-cholinesteraseinhibitorer

Country Status (16)

Country	Link
US (6)	US20040087658A1 (pl)
EP (2)	EP2260839A3 (pl)
JP (2)	JP2006506378A (pl)
KR (2)	KR100777904B1 (pl)
CN (1)	CN100339070C (pl)
AU (1)	AU2003274353B2 (pl)
CA (1)	CA2502432A1 (pl)
EA (1)	EA008863B1 (pl)
GE (1)	GEP20094759B (pl)
MX (1)	MXPA04006900A (pl)
NO (1)	NO20052462L (pl)
PL (1)	PL376476A1 (pl)
TW (1)	TW200418446A (pl)
UA (1)	UA83645C2 (pl)
WO (1)	WO2004037234A2 (pl)
ZA (1)	ZA200503204B (pl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040122090A1 (en) *	2001-12-07	2004-06-24	Lipton Stuart A.	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2003298514A1 (en) *	2002-05-17	2004-05-04	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
AU2003274353B2 (en) *	2002-10-24	2007-04-05	Merz Pharma Gmbh & Co. Kgaa	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20050113458A1 (en) *	2003-10-22	2005-05-26	Forest Laboratories, Inc.	Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
AU2005204358B2 (en) *	2004-01-05	2008-09-04	Merz Pharma Gmbh & Co. Kgaa	Memantine for the treatment of mild and mild-to-moderate Alzheimer's disease
TW200531680A (en) *	2004-03-03	2005-10-01	Merz Pharma Gmbh & Co Kgaa	Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CA2588295C (en)	2004-11-23	2013-10-22	Adamas Pharma, Llc	Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) *	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en)	2004-11-24	2006-06-01	Neuromolecular Pharmaceuticals, Inc.	Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20060211650A1 (en) *	2004-12-16	2006-09-21	Forest Laboratories, Inc.	Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
WO2006071274A2 (en) *	2004-12-23	2006-07-06	Voyager Pharmaceutical Corporation	Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20060160852A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Composition containing anti-dementia drug
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) *	2004-12-27	2013-07-09	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20060159753A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Matrix type sustained-release preparation containing basic drug or salt thereof
JP5666087B2 (ja)	2005-04-06	2015-02-12	アダマス・ファーマシューティカルズ・インコーポレーテッド	Ｃｎｓ関連疾患の治療のための方法及び組成物
JP5597343B2 (ja) *	2005-04-28	2014-10-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬を含有する組成物
US20070015834A1 (en) *	2005-07-18	2007-01-18	Moshe Flashner-Barak	Formulations of fenofibrate containing PEG/Poloxamer
TWI389709B (zh) *	2005-12-01	2013-03-21	Novartis Ag	經皮治療系統
MX2008008213A (es)	2005-12-22	2008-09-03	Neurochem Int Ltd	Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
BRPI0718437A2 (pt) *	2006-10-27	2013-11-19	Medivation Neurology Inc	Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
JP5523107B2 (ja)	2006-11-30	2014-06-18	プロビオドルグエージー	グルタミニルシクラーゼの新規阻害剤
EP2481408A3 (en)	2007-03-01	2013-01-09	Probiodrug AG	New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
EP2164489A2 (en) *	2007-07-13	2010-03-24	Eisai R&D Management Co., Ltd.	Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
US20090221554A1 (en) *	2008-02-28	2009-09-03	Zenyaku Kogyo Kabushiki Kaisha	Method of treating cognitive impairment
FR2931677B1 (fr) *	2008-06-02	2010-08-20	Sanofi Aventis	Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
TW201010691A (en) *	2008-06-12	2010-03-16	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
RU2011113733A (ru) *	2008-09-10	2012-10-20	Мерц Фарма Гмбх Унд Ко. Кгаа (De)	Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
ES2731228T3 (es) *	2009-01-20	2019-11-14	Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct	Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
MX2012002993A (es)	2009-09-11	2012-04-19	Probiodrug Ag	Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
TWI491395B (zh) *	2009-09-30	2015-07-11	Ct Lab Inc	一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
AU2010325960C1 (en)	2009-12-02	2015-08-06	Adamas Pharma, Llc	Amantadine compositions and methods of use
US20110212928A1 (en)	2010-02-09	2011-09-01	The Johns Hopkins University	Methods and compositions for improving cognitive function
TR201001117A1 (tr)	2010-02-15	2011-09-21	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Dimebolin ve memantin kombinasyonları
JP6026284B2 (ja)	2010-03-03	2016-11-16	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤
US8269019B2 (en)	2010-03-10	2012-09-18	Probiodrug Ag	Inhibitors
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
US9000047B2 (en) *	2010-05-24	2015-04-07	Farmalider, S.A.	Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses
DK3034079T3 (en)	2010-11-15	2018-02-05	Agenebio Inc	PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2013160728A1 (en)	2012-04-26	2013-10-31	Alma Mater Studiorum - Universita' Di Bologna	Dual targeting compounds for the treatment of alzheimer's disease
UA107653U (uk)	2012-10-01	2016-06-24	Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт"	Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
EP2968220B1 (en)	2013-03-15	2021-05-05	Agenebio, Inc.	Methods and compositions for improving cognitive function
WO2014144663A1 (en)	2013-03-15	2014-09-18	The Johns Hopkins University	Methods and compositions for improving cognitive function
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
CN112409363B (zh)	2013-12-20	2023-11-14	艾吉因生物股份有限公司	用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
EP3102186B1 (en) *	2014-02-04	2021-01-27	Forest Laboratories Holdings Limited	Donepezil compositions and method of treating alzheimer's disease
NZ738682A (en)	2015-05-22	2022-01-28	Agenebio Inc	Extended release pharmaceutical compositions of levetiracetam
WO2016205739A1 (en)	2015-06-19	2016-12-22	Belew Mekonnen	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR101882224B1 (ko)	2015-09-02	2018-07-26	한국프라임제약주식회사	콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물
SG11201805570WA (en)	2015-12-30	2018-07-30	Corium Int Inc	Systems and methods for long term transdermal administration
WO2017127306A1 (en)	2016-01-18	2017-07-27	Arisan Therapeutics	Adamatane derivatives for the treatment of filovirus infection
TWI736635B (zh)	2016-06-13	2021-08-21	心悅生醫股份有限公司	苯甲酸鋰之共晶及其用途
KR102403048B1 (ko)	2016-06-13	2022-05-26	신유알엑스 인터내셔널 (타이완) 코포레이션	벤조산나트륨의 공-결정 및 그의 용도
WO2017223402A1 (en)	2016-06-23	2017-12-28	Corium International, Inc.	Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
CA3031944A1 (en)	2016-07-27	2018-02-01	Corium International, Inc.	Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
AU2017301928B2 (en)	2016-07-27	2023-04-06	Corium, LLC.	Donepezil transdermal delivery system
US10945968B2 (en)	2016-07-27	2021-03-16	Corium, Inc.	Memantine transdermal delivery systems
US11369579B2 (en)	2016-10-24	2022-06-28	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en)	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2019018185A1 (en)	2017-07-15	2019-01-24	Arisan Therapeutics Inc.	ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
WO2019023239A1 (en) *	2017-07-25	2019-01-31	William Beaumont Hospital	METHODS FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE
CN117860718A (zh)	2017-08-24	2024-04-12	阿达玛斯药物有限责任公司	金刚烷胺组合物、其制备和使用方法
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
US10098861B1 (en)	2017-10-24	2018-10-16	Syneurx International (Taiwan) Corp.	Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
US11173132B2 (en)	2017-12-20	2021-11-16	Corium, Inc.	Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
US10213394B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213393B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság	Composition and method for treating neurological disease
US20190247331A1 (en)	2018-02-15	2019-08-15	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
BR112020026062B1 (pt)	2018-06-19	2023-04-04	Agenebio, Inc	Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
WO2020240505A1 (en)	2019-05-31	2020-12-03	TECNIMEDE - Sociedade Técnico-medicinal, SA	Immediate release fixed-dose combination of memantine and donepezil
FR3110393B1 (fr) *	2020-05-20	2022-05-06	Grn Consulting	Compose et composition pour induire une neuroprotection
US20240132513A1 (en)	2022-08-19	2024-04-25	Agenebio, Inc.	Benzazepine derivatives, compositions, and methods for treating cognitive impairment
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH603545A5 (pl)	1972-04-20	1978-08-31	Merz & Co
DE2856393C2 (de)	1978-12-27	1983-04-28	Merz + Co GmbH & Co, 6000 Frankfurt	Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en)	1982-07-29	1994-11-22	Merck & Co., Inc.	Controlled release drug dispersion delivery device
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
US4816456A (en) *	1986-10-01	1989-03-28	Summers William K	Administration of monoamine acridines in cholinergic neuronal deficit states
US5811128A (en)	1986-10-24	1998-09-22	Southern Research Institute	Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
NL195004C (nl) *	1987-03-04	2003-11-04	Novartis Ag	Fenylcarbamaat bevattend farmaceutisch preparaat.
US4849222A (en)	1987-03-24	1989-07-18	The Procter & Gamble Company	Mixtures for treating hypercholesterolemia
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2670680B2 (ja)	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
US5334618A (en)	1991-04-04	1994-08-02	The Children's Medical Center Corporation	Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en)	1989-03-31	1996-04-09	The Children's Medical Center Corporation	Treatment of aids dementia, myelopathy and blindness
ES2059602T3 (es)	1989-04-14	1994-11-16	Merz & Co Gmbh & Co	Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
US5912410A (en)	1990-06-15	1999-06-15	Scios Inc.	Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US5614560A (en)	1991-04-04	1997-03-25	Children's Medical Center Corporation	Method of preventing NMDA receptor-mediated neuronal damage
US5288502A (en)	1991-10-16	1994-02-22	The University Of Texas System	Preparation and uses of multi-phase microspheres
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
EP0724432B1 (en)	1993-10-22	2002-09-18	Genentech, Inc.	Methods and compositions for microencapsulation of antigens for use as vaccines
UA61962C2 (uk)	1997-06-30	2003-12-15	Мерц Фарма Гмбх Унд Ко. Кгаа	Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US6071966A (en) *	1997-06-30	2000-06-06	Merz + Co. Gmbh & Co.	1-amino-alkylcyclohexane NMDA receptor antagonists
PL198797B1 (pl) *	1999-03-31	2008-07-31	Janssen Pharmaceutica Nv	Zastosowanie wstępnie żelowanej skrobi
TW593223B (en) *	2000-06-20	2004-06-21	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
EP1509232B1 (en) *	2002-05-31	2008-11-19	H. Lundbeck A/S	A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU2003274353B2 (en) *	2002-10-24	2007-04-05	Merz Pharma Gmbh & Co. Kgaa	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20100130537A1 (en) *	2007-04-26	2010-05-27	Eisai R&D Management Co., Ltd	Cinnamide compounds for dementia

2003
- 2003-10-23 AU AU2003274353A patent/AU2003274353B2/en not_active Ceased
- 2003-10-23 JP JP2004546158A patent/JP2006506378A/ja active Pending
- 2003-10-23 GE GEAP20038812A patent/GEP20094759B/en unknown
- 2003-10-23 WO PCT/GB2003/004549 patent/WO2004037234A2/en not_active Ceased
- 2003-10-23 CN CNB200380104613XA patent/CN100339070C/zh not_active Expired - Fee Related
- 2003-10-23 MX MXPA04006900A patent/MXPA04006900A/es active IP Right Grant
- 2003-10-23 EP EP10181505A patent/EP2260839A3/en not_active Withdrawn
- 2003-10-23 US US10/691,895 patent/US20040087658A1/en not_active Abandoned
- 2003-10-23 UA UAA200504854A patent/UA83645C2/ru unknown
- 2003-10-23 EP EP03758338A patent/EP1556019A2/en not_active Withdrawn
- 2003-10-23 TW TW092129457A patent/TW200418446A/zh unknown
- 2003-10-23 KR KR1020057007052A patent/KR100777904B1/ko not_active Expired - Fee Related
- 2003-10-23 CA CA002502432A patent/CA2502432A1/en not_active Abandoned
- 2003-10-23 PL PL03376476A patent/PL376476A1/pl not_active Application Discontinuation
- 2003-10-23 KR KR1020077016542A patent/KR100852834B1/ko not_active Expired - Fee Related
- 2003-10-23 EA EA200500699A patent/EA008863B1/ru unknown
2005
- 2005-04-20 ZA ZA200503204A patent/ZA200503204B/en unknown
- 2005-05-23 NO NO20052462A patent/NO20052462L/no not_active Application Discontinuation
2008
- 2008-02-27 US US12/072,539 patent/US20090124659A1/en not_active Abandoned
2010
- 2010-03-22 US US12/661,639 patent/US20100227852A1/en not_active Abandoned
2011
- 2011-09-07 JP JP2011195242A patent/JP2011246491A/ja active Pending
2014
- 2014-05-16 US US14/280,405 patent/US20140371260A1/en not_active Abandoned
2016
- 2016-01-28 US US15/008,646 patent/US20160136144A1/en not_active Abandoned
2021
- 2021-02-18 US US17/178,606 patent/US20210169864A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20160136144A1 (en)	2016-05-19
TW200418446A (en)	2004-10-01
GEP20094759B (en)	2009-08-25
EP2260839A3 (en)	2012-05-02
ZA200503204B (en)	2006-07-26
EP2260839A2 (en)	2010-12-15
US20210169864A1 (en)	2021-06-10
EA008863B1 (ru)	2007-08-31
CN100339070C (zh)	2007-09-26
KR100777904B1 (ko)	2007-11-28
EP1556019A2 (en)	2005-07-27
WO2004037234A3 (en)	2004-08-05
US20100227852A1 (en)	2010-09-09
KR20070087161A (ko)	2007-08-27
AU2003274353A1 (en)	2004-05-13
US20040087658A1 (en)	2004-05-06
EA200500699A1 (ru)	2005-10-27
JP2011246491A (ja)	2011-12-08
MXPA04006900A (es)	2004-10-15
CA2502432A1 (en)	2004-05-06
CN1720035A (zh)	2006-01-11
UA83645C2 (ru)	2008-08-11
NO20052462D0 (no)	2005-05-23
WO2004037234A2 (en)	2004-05-06
KR20050072770A (ko)	2005-07-12
AU2003274353B2 (en)	2007-04-05
JP2006506378A (ja)	2006-02-23
KR100852834B1 (ko)	2008-08-18
PL376476A1 (pl)	2005-12-27
HK1085658A1 (zh)	2006-09-01
US20090124659A1 (en)	2009-05-14
US20140371260A1 (en)	2014-12-18

Legal Events

Date	Code	Title	Description
2013-10-07	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
EA200500699A1 (ru)	2005-10-27	Комбинированная терапия с использованием производных 1- аминоциклогексана и ингибиторов ацетилхолинэстеразы
Polinsky	1998	Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
Fang et al.	2008	Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates
NO983877D0 (no)	1998-08-21	Tropanderivater, deres fremstilling og anvendelse
Wang et al.	2018	Synthesis and biological evaluation of new tetramethylpyrazine‐based chalcone derivatives as potential anti‐Alzheimer agents
da Costa et al.	2013	Synthesis of tacrine-lophine hybrids via one-pot four component reaction and biological evaluation as acetyl-and butyrylcholinesterase inhibitors
DK1558255T3 (da)	2007-05-07	Dobbeltbindingssite acetylcholinesteraseinhibitorer til behandling af Alzheimers sygdom
Somani et al.	2015	In vitro acetylcholinesterase inhibition by psoralen using molecular docking and enzymatic studies
NO20073113L (no)	2007-07-16	Indenylderivater og anvendelse derav for behandling av neurologiske lidelser
NO20070914L (no)	2007-04-20	Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
EA200601611A1 (ru)	2007-02-27	Терапия с применением производных 1-аминоциклогексана для лечения поведенческих нарушений, ассоциированных с болезнью альцгеймера
DK217588D0 (da)	1988-04-21	17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
Reeves et al.	1999	The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease
NO20065768L (no)	2007-02-07	Karbonsamid-opioidforbindelser
NO20053341L (no)	2005-09-07	Hindring og behandling av Alzheimers sykdom.
ATE214605T1 (de)	2002-04-15	Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
BR0314430A (pt)	2005-09-27	Derivados de cicloalquilamina antidepressiva dos benzodioxanos fundidos por heterociclo
BR0314541A (pt)	2005-07-26	Tratamento de demência e doença de parkinson
DE602004009099D1 (de)	2007-10-31	Verwendung von 2-thia-dibenzoäe,hüazulenen zur behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
NO984739L (no)	1998-12-09	Spiro[cyklopent[b]indolpiperidiner og N-fenyl-hydrazon-mellomprodukter for deres fremstilling, hvor begge er acetylcholinesterase og MAO-inhibitorer
EA200602083A1 (ru)	2007-06-29	Новые пиперазиновые производные диалкилоксиндолов
WO2004028456A3 (en)	2004-06-17	Method and composition for treating neurodegenerative disorders
RU2007140876A (ru)	2009-05-20	Профилактическое или терапевтическое средство для ночного нарушения поведения, связанного со слабоумием
DE602005010694D1 (de)	2008-12-11	Piperazinderivate von alkyloxindolen
WO2005000318A3 (en)	2005-04-14	Method of inducing apoptosis and inhibiting cardiolipin synthesis